Erasca (ERAS) Set to Announce Earnings on Wednesday

Erasca (NASDAQ:ERAS) is expected to issue its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.1301) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Erasca (NASDAQ:ERAS) last released its earnings results on Tuesday, August 11th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). On average, analysts expect Erasca to post ($0.49) EPS for the current fiscal year and ($0.65) EPS for the next fiscal year.

Erasca Price Performance

NASDAQ ERAS opened at $14.64 on Wednesday. The firm has a market capitalization of $5.12 billion, a price-to-earnings ratio of -15.41 and a beta of 0.68. The company’s fifty day moving average is $15.35 and its two-hundred day moving average is $15.04. Erasca has a 52-week low of $2.11 and a 52-week high of $24.28.

Analysts Set New Price Targets

A number of brokerages have recently commented on ERAS. Guggenheim upped their price objective on shares of Erasca from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Jefferies Financial Group reissued a “buy” rating on shares of Erasca in a research report on Tuesday, July 14th. Morgan Stanley upped their price target on Erasca from $12.00 to $21.00 and gave the company an “equal weight” rating in a report on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Erasca in a report on Tuesday, September 8th. Finally, Bank of America raised their price objective on Erasca from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Friday, August 14th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $22.09.

About Erasca

Erasca, Inc (NASDAQ: ERAS) is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with RAS/MAPK pathway-driven cancers. The company’s research and development programs are designed to target molecular alterations that contribute to tumor growth and treatment resistance, including mutations involving the RAS family of proteins and related signaling pathways.

Erasca’s pipeline has included small-molecule oncology candidates such as naporafenib, a pan-RAF inhibitor being studied in cancers with aberrant RAS/MAPK signaling, as well as additional investigational therapies intended to address difficult-to-treat oncogenic drivers.